Latest News and Press Releases
Want to stay updated on the latest news?
Search Results
Everything
Search Filters
-
Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer
MELBOURNE, Australia and OXFORD, United Kingdom, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing precisely targeted next-generation immunotherapies for...
-
MELBOURNE, Australia and OXFORD, United Kingdom, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe,...
-
MELBOURNE, Australia, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe, convenient, and precisely...
-
Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and current asthma MELBOURNE, Australia, June 04, 2019 (GLOBE NEWSWIRE) -- Aravax, a clinical stage...
-
Data show that PVX108 demonstrates exceptional safety in adults with peanut allergy MELBOURNE, Australia, May 28, 2019 (GLOBE NEWSWIRE) -- Aravax, a clinical stage biotechnology company focused...
-
Data show that PVX108, a peptide-based immunotherapy, has a highly favorable safety profile for the treatment of peanut allergy MELBOURNE, Australia, Feb. 24, 2019 (GLOBE NEWSWIRE) -- Aravax, a...
-
Study designed to evaluate safety and tolerability of a novel peptide-based immunotherapy to treat peanut allergies MELBOURNE, Australia, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Aravax, a clinical stage...